The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer

Growth Factor ◽

Kinase Inhibitor ◽

Osteoclast Differentiation ◽

Growth Factor Receptor ◽

Bone Destruction ◽

Vascular Endothelial ◽

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The Oncologist ◽

10.1002/onco.13897 ◽

2021 ◽

Author(s):

Akhilesh Sivakumar ◽

Sarah E. Caulfield ◽

Chao Zhang ◽

Subir Goyal ◽

Mehmet A. Bilen ◽

...

Keyword(s):

Retrospective Study ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)80145-9 ◽

2004 ◽

Vol 2 (8) ◽

pp. 44 ◽

Cited By ~ 6

Author(s):

A. Tolcher ◽

J.J. O'Leary ◽

J. DeBono ◽

K. Molpus ◽

C. Woodard ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Tyrosine Kinase Inhibitor ◽

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research ◽

10.1158/0008-5472.can-07-5809 ◽

2008 ◽

Vol 68 (12) ◽

pp. 4754-4762 ◽

Cited By ~ 86

Author(s):

Caroline A. Heckman ◽

Tanja Holopainen ◽

Maria Wirzenius ◽

Salla Keskitalo ◽

Michael Jeltsch ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

NMR in Biomedicine ◽

10.1002/nbm.961 ◽

2005 ◽

Vol 18 (5) ◽

pp. 308-321 ◽

Cited By ~ 44

Author(s):

Markus Rudin ◽

Paul M. J. McSheehy ◽

Peter R. Allegrini ◽

Martin Rausch ◽

Diana Baumann ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Contrast Agent ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal Of Pathology ◽

10.2353/ajpath.2008.071074 ◽

2008 ◽

Vol 173 (1) ◽

pp. 265-277 ◽

Cited By ~ 59

Author(s):

Cornelia Halin ◽

Hermann Fahrngruber ◽

Josef G. Meingassner ◽

Guido Bold ◽

Amanda Littlewood-Evans ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Skin Inflammation ◽

Vascular Endothelial ◽

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo

Angiogenesis ◽

10.1007/s10456-009-9151-7 ◽

2009 ◽

Vol 12 (3) ◽

pp. 287-296 ◽

Cited By ~ 4

Author(s):

Kenneth R. LaMontagne ◽

Jeannene Butler ◽

Virna B. Borowski ◽

Angel R. Fuentes-Pesquera ◽

Jonathan M. Blevitt ◽

...

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Orally Bioavailable ◽

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization

Ophthalmic Research ◽

10.1159/000324994 ◽

2012 ◽

Vol 47 (1) ◽

pp. 13-18 ◽

Cited By ~ 12

Author(s):

Uğurcan Keskin ◽

Yüksel Totan ◽

Remzi Karadağ ◽

Mesut Erdurmuş ◽

Bahri Aydın

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Corneal Neovascularization ◽

Vascular Endothelial ◽

Inhibitory Effects ◽

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Cancer Research ◽

10.1158/0008-5472.can-04-4409 ◽

2005 ◽

Vol 65 (10) ◽

pp. 4389-4400 ◽

Cited By ~ 542

Author(s):

Stephen R. Wedge ◽

Jane Kendrew ◽

Laurent F. Hennequin ◽

Paula J. Valentine ◽

Simon T. Barry ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Orally Bioavailable ◽

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-2436 ◽

2010 ◽

Vol 16 (7) ◽

pp. 2187-2197 ◽

Cited By ~ 10

Author(s):

Marlies H.G. Langenberg ◽

Petronella O. Witteveen ◽

Jeanine M. Roodhart ◽

Henk M.W. Verheul ◽

Marja Mergui-Roelvink ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽